Drug profile · INN
sodium zirconium cyclosilicate
LOKELMA
sodium zirconium cyclosilicate (LOKELMA) is a potassium chelating agent. Route of administration: oral. Current US regulatory status: approved.
Drug details — sodium zirconium cyclosilicate
- US status
- approved
- Class
- Various (V03)
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
sodium zirconium cyclosilicate (LOKELMA) is a potassium chelating agent. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Potassium chelating agent
Primary target: Potassium
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sodium zirconium cyclosilicate?
sodium zirconium cyclosilicate (LOKELMA) is a potassium chelating agent. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sodium zirconium cyclosilicate?
LOKELMA is a marketed brand name for sodium zirconium cyclosilicate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sodium zirconium cyclosilicate?
sodium zirconium cyclosilicate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.